50829 Köln, de
+49 (221) 222529-41
AYOXXA BIOSYSTEMS Appoints Dr. Gerald Möller as Chairman of the Board
AYOXXA BIOSYSTEMS Appoints Dr. Gerald Möller as Chairman of the Board Company directs its powerful multiplex platform to unlock the power of proteomics in precision medicine
In the early commercialization phase AYOXXA’s customers gave very encouraging feedback and have seen how LUNARIS™ multiplex protein quantification platform is helping them to answer important questions about complex diseases and personalized medicine.
Rainer Christine comments: “It was a great pleasure for me to be an investor and the chairman of AYOXXA during the company’s early stages. With the launch of its first products, AYOXXA is now entering a new phase. I am thrilled that Dr. Gerald Möller will from now on chair AYOXXA’s board and bring to bear his vast experience and excellent reputation in the field.”
Dr. Andreas Schmidt CEO and Co-founder of AYOXXA Biosystems GmbH comments: “I am excited about his commitment as new chairmen and investor of AYOXXA. What we see in genomics will be complemented by better understanding the power of proteomics. With Gerald Möller we found an experienced international leader to take up this challenge together with the board and management of AYOXXA.
“Over the last years I have been active in the fields of genomics and tissue phenomics and supported their important and growing impact in precision medicine. I am excited about the potential of the AYOXXA multiplexing platform which could become a strong vehicle to unlock the power of proteomics in the discovery and development of new diagnostics and therapeutics, both in academia and industry. With the first products moving into the markets it is an optimal time for me to join and help. I am impressed by what the people at AYOXXA have accomplished so far”, says Dr. Gerald Möller.
About Dr. Gerald Möller
Dr. Gerald Möller has about 40 years of management experience in the Diagnostic and Pharmaceutical Industries. From 1975-1998 he held several senior management positions in the global organization of Boehringer Mannheim, where he became CEO of the worldwide operating Group in 1995. Following the sale of Boehringer Mannheim to Roche, he became member of Roche’s Executive Committee till December 1998. Moeller was an Investment Advisor to HMB Partners, Switzerland from 2002 to 2014 and an active participant in the international Healthcare/Biotechnology sector serving on the board of many innovative growing companies, most of which were successfully sold to large, global Healthcare firms. He served 5 years on the Board of Illumina Inc. which he left in May 2015. He is Chairman of Morphosys AG in Germany.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.